Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells

Background: Chondromodulin-I (CHM1) sustains malignancy in Ewing sarcoma (ES). Refractory ES carries a dismal prognosis and patients with bone marrow (BM) metastases do not survive irrespective of therapy. We assessed HLA-A*02:01/CHM1-specific allorestricted T cell receptor (TCR) wild-type and trans...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncoimmunology
Asıl Yazarlar: Thiel, Uwe, Schober, Sebastian J., Einspieler, Ingo, Kirschner, Andreas, Thiede, Melanie, Schirmer, David, Gall, Katja, Blaeschke, Franziska, Schmidt, Oxana, Jabar, Susanne, Ranft, Andreas, Alba Rubío, Rebeca, Dirksen, Uta, Grunewald, Thomas G. P., Sorensen, Poul H., Richter, Günther H. S., von Lüttichau, Irene Teichert, Busch, Dirk H., Burdach, Stefan E. G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2017
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467994/
https://ncbi.nlm.nih.gov/pubmed/28638739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1312239
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller